Vose J M, Armitage J O
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 69189-3330.
Annu Rev Med. 1993;44:255-63. doi: 10.1146/annurev.me.44.020193.001351.
The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.
在过去几年中，高剂量化疗联合自体移植治疗复发性或高危淋巴瘤患者的方法有了极大的拓展。随着新型抗生素和造血生长因子等新的支持性治疗措施的应用，与该疗法相关的发病率和死亡率有所降低。这反过来又使得该疗法能够在疾病进程中更早地成功应用，从而提高了无病生存率。未来的试验将致力于利用新的治疗方法和支持性治疗措施进一步改善治疗效果。
